A rational targeted therapy for platinum-resistant small-cell lung cancer
- PMID: 33848475
- DOI: 10.1016/j.ccell.2021.03.003
A rational targeted therapy for platinum-resistant small-cell lung cancer
Abstract
Small-cell lung cancer (SCLC) is initially sensitive to platinum doublet chemotherapy, providing dramatic clinical benefit. Unfortunately, most SCLCs relapse and become resistant to further therapy. In this issue of Cancer Cell, Thomas et al. show that some platinum-resistant SCLCs benefit from combination therapy with topotecan plus the ATR (ataxia telangiectasia-mutated and rad3-related) inhibitor berzosertib.
Copyright © 2021. Published by Elsevier Inc.
Conflict of interest statement
Declaration of interests J.D.M. receives NCI and UT Southwestern licensing royalties for distribution of human tumor lines.
Comment on
-
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.Cancer Cell. 2021 Apr 12;39(4):566-579.e7. doi: 10.1016/j.ccell.2021.02.014. Cancer Cell. 2021. PMID: 33848478 Free PMC article.
Similar articles
-
Topotecan as first-line therapy for small cell lung cancer.Lung Cancer. 2003 Aug;41 Suppl 4:S9-16. doi: 10.1016/s0169-5002(03)90520-4. Lung Cancer. 2003. PMID: 14565509
-
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.Cancer Cell. 2021 Apr 12;39(4):566-579.e7. doi: 10.1016/j.ccell.2021.02.014. Cancer Cell. 2021. PMID: 33848478 Free PMC article.
-
Topotecan: a review of its efficacy in small cell lung cancer.Drugs. 1999 Sep;58(3):533-51. doi: 10.2165/00003495-199958030-00020. Drugs. 1999. PMID: 10493279 Review.
-
Update on the role of topotecan in the treatment of non-small cell lung cancer.Oncologist. 2004;9 Suppl 6:43-52. doi: 10.1634/theoncologist.9-90006-43. Oncologist. 2004. PMID: 15616149 Review.
-
Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.Cancer Chemother Pharmacol. 2008 Nov;62(6):1009-14. doi: 10.1007/s00280-008-0690-1. Epub 2008 Feb 8. Cancer Chemother Pharmacol. 2008. PMID: 18259751 Clinical Trial.
Cited by
-
Long non-coding RNA ANRIL promotes homologous recombination-mediated DNA repair by maintaining ATR protein stability to enhance cancer resistance.Mol Cancer. 2021 Jul 5;20(1):94. doi: 10.1186/s12943-021-01382-y. Mol Cancer. 2021. PMID: 34225755 Free PMC article. No abstract available.
-
Enabling programmable dynamic DNA chemistry using small-molecule DNA binders.Nat Commun. 2023 Jul 17;14(1):4248. doi: 10.1038/s41467-023-40032-3. Nat Commun. 2023. PMID: 37460620 Free PMC article.
-
Current research progress in targeted anti-angiogenesis therapy for osteosarcoma.Cell Prolif. 2021 Sep;54(9):e13102. doi: 10.1111/cpr.13102. Epub 2021 Jul 26. Cell Prolif. 2021. PMID: 34309110 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous